NasdaqCM - Delayed Quote • USD
Aldeyra Therapeutics, Inc. (ALDX)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 4:43 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 5 |
| Avg. Estimate | -0.11 | -0.13 | -0.19 | -0.41 |
| Low Estimate | -0.21 | -0.17 | -0.72 | -0.8 |
| High Estimate | 0.02 | -0.08 | 1.15 | 0.55 |
| Year Ago EPS | -0.27 | -0.15 | -0.64 | -0.19 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 5 | 4 |
| Avg. Estimate | 2M | -- | 39.8M | 51.71M |
| Low Estimate | -- | -- | -- | 18.7M |
| High Estimate | 6M | -- | 100M | 100M |
| Year Ago Sales | -- | -- | -- | 39.8M |
| Sales Growth (year/est) | -- | -- | -- | 29.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.29 | -0.31 | -0.24 | -0.14 |
| EPS Actual | -0.27 | -0.15 | -0.14 | -0.08 |
| Difference | 0.02 | 0.16 | 0.1 | 0.06 |
| Surprise % | 6.90% | 51.60% | 41.70% | 42.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.11 | -0.13 | -0.19 | -0.41 |
| 7 Days Ago | -0.11 | -0.13 | -0.19 | -0.41 |
| 30 Days Ago | -0.11 | 0.11 | 0.08 | -0.36 |
| 60 Days Ago | -0.14 | 0.88 | -0.15 | -0.68 |
| 90 Days Ago | -0.18 | 0.57 | -0.44 | -0.99 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ALDX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 59.30% | -- | -- | 0.80% |
| Next Qtr. | 13.30% | -- | -- | 9.60% |
| Current Year | 70.30% | -- | -- | 4.50% |
| Next Year | -115.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 73.70% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Upgrade | Oppenheimer: Perform to Outperform | 4/3/2024 |
| Maintains | Citigroup: Buy to Buy | 10/17/2023 |
| Downgrade | Oppenheimer: Outperform to Perform | 10/17/2023 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/30/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/22/2023 |
Related Tickers
FGEN FibroGen, Inc.
1.1700
-7.87%
ARDX Ardelyx, Inc.
6.44
-1.68%
ADMA ADMA Biologics, Inc.
6.20
+2.65%
AKBA Akebia Therapeutics, Inc.
1.3900
0.00%
HRTX Heron Therapeutics, Inc.
2.7100
-2.17%
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0200
-5.63%
ALT Altimmune, Inc.
6.89
-2.13%
TGTX TG Therapeutics, Inc.
13.99
+1.23%
CDTX Cidara Therapeutics, Inc.
0.7220
-0.03%
LPTX Leap Therapeutics, Inc.
2.9600
-1.33%